S Bank Fund Management Ltd Acquires 30,457 Shares of Illumina, Inc. $ILMN

S Bank Fund Management Ltd boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1,973.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,000 shares of the life sciences company’s stock after purchasing an additional 30,457 shares during the quarter. S Bank Fund Management Ltd’s holdings in Illumina were worth $4,197,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its position in Illumina by 17.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock worth $79,081,000 after acquiring an additional 124,246 shares during the last quarter. Elo Mutual Pension Insurance Co bought a new stake in Illumina during the third quarter valued at about $2,319,000. Caprock Group LLC acquired a new stake in shares of Illumina in the third quarter valued at about $1,479,000. Nordea Investment Management AB increased its stake in shares of Illumina by 148.6% in the third quarter. Nordea Investment Management AB now owns 32,657 shares of the life sciences company’s stock worth $3,024,000 after purchasing an additional 19,519 shares during the period. Finally, Rakuten Investment Management Inc. bought a new position in shares of Illumina in the third quarter worth about $861,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 0.2%

ILMN stock opened at $139.07 on Wednesday. Illumina, Inc. has a twelve month low of $73.86 and a twelve month high of $155.53. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The company has a market cap of $21.13 billion, a PE ratio of 25.29, a price-to-earnings-growth ratio of 2.31 and a beta of 1.42. The business’s 50-day simple moving average is $126.11 and its 200 day simple moving average is $127.23.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the company earned $0.97 EPS. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, research analysts anticipate that Illumina, Inc. will post 5.2 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Patricia Leckman sold 2,370 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on ILMN shares. Barclays increased their target price on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research note on Friday. Weiss Ratings lowered Illumina from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. UBS Group reissued a “neutral” rating and issued a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. Evercore restated an “outperform” rating on shares of Illumina in a research note on Friday. Finally, Guggenheim boosted their target price on shares of Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Six analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $131.06.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.